Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
NovoCure device slows spread of lung cancer to brain in late-stage study; shares rise
11:00am, Wednesday, 27'th Mar 2024
Novocure (NASDAQ:NVCR) shares soared on Wednesday as the oncology firm revealed its investigational medical device slowed the spread of cancer to the brain in patients with lung cancer during a late-
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demo
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
09:16am, Wednesday, 27'th Mar 2024
Novocure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening.
Novocure's lung cancer therapy succeeds in late-stage trial
07:12am, Wednesday, 27'th Mar 2024
Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement i
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
10:56am, Wednesday, 13'th Mar 2024
The mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
07:00am, Monday, 11'th Mar 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 /
NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates
09:26am, Thursday, 22'nd Feb 2024
NovoCure (NVCR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.36 per share a year ago.
Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?
08:50am, Friday, 19'th Jan 2024
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%
11:40pm, Tuesday, 12'th Dec 2023
Wall Street loves a good comeback story. It's why analysts often put elevated price targets on severely beaten-down stocks.
Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts
10:51am, Tuesday, 28'th Nov 2023
Novocure (NASDAQ: NVCR ) layoffs are in the news after the company announced that it will be cutting 13% of its workers in a restructuring effort. Those layoffs will see the oncology company reducing
NovoCure: Significant Upside Even Without A Breakthrough
07:54pm, Thursday, 16'th Nov 2023
NovoCure is an oncology company that offers a novel therapy for solid tumors called TTFields and comprehensive patient support services. Despite a challenging year, NovoCure's core business is healthy
Is Novocure Stock a Buy?
06:45am, Friday, 03'rd Nov 2023
Novocure has a novel and original way to treat cancer. However, the company's financial results haven't been great.
Why Novocure Stock Was Sick Today
04:35pm, Thursday, 26'th Oct 2023
The cancer treatment device developer released its latest set of quarterly results. These were a mixed bag, as it notched a beat on earnings but missed on revenue.
3 Things About NovoCure That Smart Investors Know
10:15am, Tuesday, 19'th Sep 2023
NovoCure doesn't have any direct competitors for its anti-cancer device. The product could see its indications expanded into various other niches.
